Salvage surgery in head and neck cancer: Does it improve outcomes?


Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356

Informations de publication

Date de publication:
06 2020
Historique:
received: 15 09 2019
revised: 18 12 2019
accepted: 12 01 2020
pubmed: 6 2 2020
medline: 16 12 2020
entrez: 5 2 2020
Statut: ppublish

Résumé

Studies reporting outcomes of salvage surgery in locally advanced head and neck squamous cell carcinoma (LAHNSCC) have inherent biases like biological and temporal selection. Our study considered all patients deemed fit for salvage surgery and compared to those who underwent surgery versus those who refused it thus throwing light on the real world benefit of salvage surgery. This was a post hoc analysis of a phase 3 randomized trial conducted between 2012 and 2018. Out of 536 LAHNSCC patients randomised in the study, 113 patients had residual disease or recurrent disease and were planned for salvage surgery in a multidisciplinary clinic. Patients were divided into 2 cohorts for comparison, willing for salvage surgery (n = 91) and unwilling for salvage surgery(n = 22). The primary endpoint was overall survival. The median follow up was 28.7 months (95%CI 23.9-33.5 months). Out of the 91 patients who were willing for salvage surgery, 78 underwent same. The median survival in cohort of patients willing for salvage surgery was 22.0 months (95%CI 10.1-33.9) while it was 9.7 months (95%CI 6.6-12.8) in patients who were unwilling for salvage surgery (HR = 0.262 95%CI HR 0.147-0.469, p = 0.000). Salvage surgery leads to a substantial improvement in outcomes in head and neck cancers and should be the de facto standard of care in patients who are eligible for the same.

Sections du résumé

BACKGROUND
Studies reporting outcomes of salvage surgery in locally advanced head and neck squamous cell carcinoma (LAHNSCC) have inherent biases like biological and temporal selection. Our study considered all patients deemed fit for salvage surgery and compared to those who underwent surgery versus those who refused it thus throwing light on the real world benefit of salvage surgery.
METHODS
This was a post hoc analysis of a phase 3 randomized trial conducted between 2012 and 2018. Out of 536 LAHNSCC patients randomised in the study, 113 patients had residual disease or recurrent disease and were planned for salvage surgery in a multidisciplinary clinic. Patients were divided into 2 cohorts for comparison, willing for salvage surgery (n = 91) and unwilling for salvage surgery(n = 22). The primary endpoint was overall survival.
RESULTS
The median follow up was 28.7 months (95%CI 23.9-33.5 months). Out of the 91 patients who were willing for salvage surgery, 78 underwent same. The median survival in cohort of patients willing for salvage surgery was 22.0 months (95%CI 10.1-33.9) while it was 9.7 months (95%CI 6.6-12.8) in patients who were unwilling for salvage surgery (HR = 0.262 95%CI HR 0.147-0.469, p = 0.000).
CONCLUSION
Salvage surgery leads to a substantial improvement in outcomes in head and neck cancers and should be the de facto standard of care in patients who are eligible for the same.

Identifiants

pubmed: 32014275
pii: S0748-7983(20)30024-X
doi: 10.1016/j.ejso.2020.01.019
pii:
doi:

Types de publication

Clinical Trial, Phase III Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1052-1058

Informations de copyright

Copyright © 2020. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of competing interest None of the other authors have anything to declare that maybe considered as potential competing interests.

Auteurs

Vijay Maruti Patil (VM)

Department of Medical Oncology, Tata Memorial Hospital, HBNI, Mumbai, India.

Vanita Noronha (V)

Department of Medical Oncology, Tata Memorial Hospital, HBNI, Mumbai, India.

Shivakumar Thiagarajan (S)

Department of Head and Neck Surgery, Tata Memorial Hospital, HBNI, Mumbai, India.

Amit Joshi (A)

Department of Medical Oncology, Tata Memorial Hospital, HBNI, Mumbai, India.

Arun Chandrasekharan (A)

Department of Medical Oncology, Tata Memorial Hospital, HBNI, Mumbai, India.

Vikas Talreja (V)

Department of Medical Oncology, Tata Memorial Hospital, HBNI, Mumbai, India.

Jaiprakash Agarwal (J)

Department of Radiation Oncology, Tata Memorial Hospital, HBNI, Mumbai, India.

Sarbani Ghosh-Laskar (S)

Department of Radiation Oncology, Tata Memorial Hospital, HBNI, Mumbai, India.

Ashwini Budrukkar (A)

Department of Radiation Oncology, Tata Memorial Hospital, HBNI, Mumbai, India.

Shashikant Juvekar (S)

Department of Radiology, Tata Memorial Hospital, HBNI, Mumbai, India.

Abhishek Mahajan (A)

Department of Radiology, Tata Memorial Hospital, HBNI, Mumbai, India.

Archi Agarwal (A)

Department of Nuclear Medicine, Tata Memorial Hospital, HBNI, Mumbai, India.

Nilendu Purandare (N)

Department of Nuclear Medicine, Tata Memorial Hospital, HBNI, Mumbai, India.

Atanu Bhattacharjee (A)

Department of Epidemiology, Advanced Centre for Treatment, Research and Education in Cancer, Navi Mumbai, India.

Anil K D'Cruz (AK)

Department of Head and Neck Surgery, Tata Memorial Hospital, HBNI, Mumbai, India.

Pankaj Chaturvedi (P)

Department of Head and Neck Surgery, Tata Memorial Hospital, HBNI, Mumbai, India.

Prathamesh S Pai (PS)

Department of Head and Neck Surgery, Tata Memorial Hospital, HBNI, Mumbai, India.

Devendra Chaukar (D)

Department of Head and Neck Surgery, Tata Memorial Hospital, HBNI, Mumbai, India.

Kumar Prabhash (K)

Department of Medical Oncology, Tata Memorial Hospital, HBNI, Mumbai, India. Electronic address: kumarprabhashtmh@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH